Meeting
2020 ASCO Virtual Scientific Program
A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment.
Authors
Anthony B. El-Khoueiry
Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA
Anthony B. El-Khoueiry , Nishan Tchekmedyian , Rachel E. Sanborn , Julio Antonio Peguero , Kerry Pulver , Vikas Dembla , Jacob Stephen Thomas , Gary Gene Chiang , Mark Densel , Neil Sankar , Stephen Theodore Worland , Lyon L. Gleich , Robert S. Sikorski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT03616834
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3112)
DOI
10.1200/JCO.2020.38.15_suppl.3112
Abstract #
3112
Poster Bd #
176
Abstract Disclosures
Similar Posters
First Author: Jeddeo Paul
Poster
2016 ASCO Annual Meeting
Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC).
First Author: Rathi Narayana Pillai
First Author: Igor Tsaur
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu